Login to Your Account



OSE, Effimune combine immunotherapy efforts in $34M stock deal

By Cormac Sheridan
Staff Writer

Wednesday, February 24, 2016

DUBLIN – French immunotherapy firmsOSE Pharma SA and Effimune SAS are pooling their resources in a stock-based transaction, with the aim of creating scale in a rapidly moving field. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription